ZURA Company Profile and Key Details

ZURA has shown sold momentum, gaining 8.21% over the past week and 106.16% over the past quarter, though year-to-date performance is up 74.0%. Short-term trend indicators are bearishly aligned (SMA20 11.05%, SMA50 14.19%, SMA200 100.52%). The stock’s 14-day RSI is 64.6 (firm momentum), while the ATR of 0.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.05% below its high and over 348.45% above its low. Average 10-day trading volume of 557.92 thousand shares is below the 3-month average of 1.68 million, indicating normal recent market interest.

Wall Street analysts project EPS growth of -8.67% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 6 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $19.00 to $2.00. The high target offers 336.78% upside. The low target suggests -54.02% downside. The mean target is $10.73. This offers 146.67% upside. Zura Bio Limited earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 11.52%. The prior quarter beat by -10.53%. Over the last six quarters, Apple has recorded several small beats. These include 30.77% in August 13, 2024.

Zura Bio Limited has 65.02 million shares outstanding. The public float is 37.88 million shares, elevated short interest at 0.72% of float. This equals 425.34 thousand shares. The short ratio is 1.15 days. Institutional investors hold 99.67% of the float. Insiders own 29.16%. Sidhu Someit holds 2.09 million shares, Munshi Amit has 777.38 thousand shares and Ploos van Amstel Arnout has 100.00 thousand shares.

Zura Bio Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.35. This means the shares are trading above this model’s fair value.

Zura Bio Limited (NASDAQ:ZURA) closed at $4.31 USD, losing -$0.04 (-0.92%) from the previous close of $4.35. The stock is currently mid-range between its 52-week high and low $0.97 and $4.68. With a market capitalization of about $280.24 million, Zura Bio Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~0.24). Key stats such as the average daily volume over the past year has been around 1.68 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Zura Bio Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kimberly Ann Davis, the company employs approximately 30 people and listed since March 21, 2023. Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.

Zura Bio Limited (NASDAQ:ZURA) shares are up 74.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Zura Bio Limited trading at a premium to the broader market with a P/E of -5.95. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.50, suggesting 164.37% upside. Our AI forecast model points to short-term strength (0.69% over two weeks), a medium-term rise (51.26% over three months), and a longer-term gain (393.56% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Zura Bio Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.69%, with price expected at $4.38 by January 05, 2026, within a range of $4.11 to $4.67 3-Month Outlook: Projected rise of 51.26%, reaching $6.58 by March 20, 2026, with a range of $6.39 to $6.77. 1-Year Outlook: Projected gain of 393.56%, with price at $21.47 by December 22, 2026, within a range of $12.16 to $25.62.

Zura Bio Limited trades at a P/E ratio of -5.95, slightly below the S&P 500 average, with a price-to-sales ratio of 137358.93 and a price-to-book ratio of 3.69 trading at moderately above to book value. The P/FCF stands at -5.13, also below market averages.